Explore the words cloud of the SCAUT project. It provides you a very rough idea of what is the project "SCAUT" about.
The following table provides information about the project.
|Coordinator Country||Netherlands [NL]|
|Total cost||3˙984˙850 €|
|EC max contribution||2˙998˙374 € (75%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2019-01-01 to 2021-12-31|
Take a look of project's partnership.
|1||LABONOVUM BV||NL (LIMMEN)||coordinator||761˙687.00|
|2||BLOK SYSTEM SUPPLY BV||NL (AMSTERDAM)||participant||1˙540˙087.00|
|3||CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER||FR (MONTPELLIER)||participant||453˙875.00|
|4||YEREVAN STATE MEDICAL UNIVERSITY AFTER MKHITAR HERATSI||AM (YEREVAN)||participant||242˙725.00|
95% of blood collected via venipuncture is not used for diagnostic measurements, and needs to be disposed as biohazardous waste by incineration, which is incredibly wasteful and taxing on our environment. In Europe, there is an urgent need for innovative approaches that engage vulnerable groups and increase access to infectious disease testing by breaking-down social and logistic barriers to healthcare. The decentralization of healthcare have created a need for a simple, safe, standardized and painless collection of serum specimens. The Ser-Col® is a novel serum separation device that simplifies and combines both blood collection and serum separation. With a few drops of blood from a finger stick, serum can be collected which is stable for several months prior to analysis of clinically relevant serum parameters, and thereby reducing biohazardous waste production by 50%. Ser-Col simplifies and reduces the cost of serum sampling by replacing the blood tube, trained personnel, cold storage, and centrifuge with a reliable and easy to use device that links target population to centralized diagnostics laboratories, ultimately leading to the long-term reduction of the burden of infectious diseases. The SCAUT consortium will scale up manufacturing to deliver a market ready version of the Ser-Col and validate its clinical performance against existing standards. To ensure market uptake the consortium will develop an automated serum processing platform for optimal compatibility with exciting laboratory diagnostic equipment and facilitate adoption of Ser-Col by healthcare professionals. This will accelerate commercialization, attract investors and to establish industry partnerships required to realize the full potential of the technology. The SCAUT project seeks to obtain €3 million to finalize the analytical and clinical validation and go-to-market of the Ser-Col® device. The estimated cumulative profit is €463.813 in 2023 increasing towards €18 million in 2027.
|Project website||Websites, patent fillings, videos etc.||2020-01-30 08:24:10|
Take a look to the deliverables list in detail: detailed list of SCAUT deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SCAUT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SCAUT" are provided by the European Opendata Portal: CORDIS opendata.